Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMAZE 12 weight-loss maintenance study of zenagamtide in adults with obesity
NL-OMON61078Phase 3Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- May 2026
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obesity comparing Zenagamtide with Placebo (2 arms). Primary endpoint: Relative change in body weight. Started May 2026; status: active, not recruiting.
02
Drugs
amycretin
03
Conditions
obesity
Beyond the preview
Go deeper on NL-OMON61078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61078.